×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BMY – bristol-myers squibb company (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BMY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/24
06:01 pm
bmy
Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever [Yahoo! Finance]
Low
Report
Got $1,000? 2 High-Yield Healthcare Stocks to Buy and Hold Forever [Yahoo! Finance]
12/24
12:20 pm
bmy
Global Healthy Living Foundation Expands Access to Education and Clinical Trial Information for Spanish-Speaking Lupus Communities [Yahoo! Finance]
Low
Report
Global Healthy Living Foundation Expands Access to Education and Clinical Trial Information for Spanish-Speaking Lupus Communities [Yahoo! Finance]
12/24
02:00 am
bmy
Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is Over - It's Not [Seeking Alpha]
Low
Report
Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is Over - It's Not [Seeking Alpha]
12/23
10:54 pm
bmy
Is Bristol Myers Squibb (BMY) Still Undervalued After Its Recent Share Price Rebound? [Yahoo! Finance]
Low
Report
Is Bristol Myers Squibb (BMY) Still Undervalued After Its Recent Share Price Rebound? [Yahoo! Finance]
12/23
05:48 pm
bmy
Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact [Yahoo! Finance]
Low
Report
Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact [Yahoo! Finance]
12/23
11:31 am
bmy
Bristol-Myers Squibb: Pharma Giant Still Undervalued And Printing Cash Despite Patent Cliff [Seeking Alpha]
Low
Report
Bristol-Myers Squibb: Pharma Giant Still Undervalued And Printing Cash Despite Patent Cliff [Seeking Alpha]
12/23
11:18 am
bmy
Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued [Seeking Alpha]
Low
Report
Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued [Seeking Alpha]
12/23
08:46 am
bmy
Bristol-Myers Squibb: Still Undervalued And Generating 4.65% Dividend Yield [Seeking Alpha]
Low
Report
Bristol-Myers Squibb: Still Undervalued And Generating 4.65% Dividend Yield [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
10/31/2025
04:03 pm
bmy
bristol-myers squibb company
BEAT
Report
-0.1%
bristol-myers squibb company
10/30/2025
04:03 pm
bmy
bristol-myers squibb company
BEAT
Report
1.0%
bristol-myers squibb company
10/30/2025
09:06 am
bmy
bristol-myers squibb company
BEAT
Report
5.5%
bristol-myers squibb company
7/31/2025
04:03 pm
bmy
bristol-myers squibb company
BEAT
Report
2.1%
bristol-myers squibb company
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/18
04:42 pm
bmy
Form 8-K BRISTOL MYERS SQUIBB CO For: Nov 17
Medium
Report
Form 8-K BRISTOL MYERS SQUIBB CO For: Nov 17
11/12
10:07 am
bmy
Form CERT BRISTOL MYERS SQUIBB CO
Low
Report
Form CERT BRISTOL MYERS SQUIBB CO
11/10
04:46 pm
bmy
Form 8-A12B BRISTOL MYERS SQUIBB CO
Medium
Report
Form 8-A12B BRISTOL MYERS SQUIBB CO
11/10
04:07 pm
bmy
Form 8-K BRISTOL MYERS SQUIBB CO For: Oct 31
Medium
Report
Form 8-K BRISTOL MYERS SQUIBB CO For: Oct 31
11/5
04:51 pm
bmy
Form FWP BRISTOL MYERS SQUIBB CO Filed by: BRISTOL MYERS SQUIBB CO
Low
Report
Form FWP BRISTOL MYERS SQUIBB CO Filed by: BRISTOL MYERS SQUIBB CO
11/4
05:20 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Nov 03 Filed by: Lenkowsky Adam
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Nov 03 Filed by: Lenkowsky Adam
11/4
05:18 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Nov 01 Filed by: BOERNER CHRISTOPHER S.
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Nov 01 Filed by: BOERNER CHRISTOPHER S.
11/4
05:16 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Nov 01 Filed by: Meyers Gregory Scott
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Nov 01 Filed by: Meyers Gregory Scott
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/24
Bristol-Myers releases mixed Opdivo lung cancer results [Reuters]
10.2%
3/12 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: LEUNG SANDRA 7.9%
3/25 Form DEF 14A BRISTOL MYERS SQUIBB CO For: May 05 5.9%
4/8 Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer 4.3%
3/3 Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology 3.9%
4/3 Form 3 BRISTOL MYERS SQUIBB CO For: Mar 30 Filed by: Mily Elizabeth 3.4%
8/25 Better Buy: Biogen vs. Celgene [The Motley Fool] 3.1%
3/31 Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA 2.8%
4/20 Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma 2.8%
8/15 What Has Led Bristol-Myers Squibb's Stock To Fall More Than 35% Over The Last 3 Years? [Forbes] 2.7%
3/12 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: LEUNG SANDRA 7.9%
3/25 Form DEF 14A BRISTOL MYERS SQUIBB CO For: May 05 5.9%
4/8 Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer 4.3%
3/3 Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology 3.9%
4/3 Form 3 BRISTOL MYERS SQUIBB CO For: Mar 30 Filed by: Mily Elizabeth 3.4%
8/25 Better Buy: Biogen vs. Celgene [The Motley Fool] 3.1%
3/31 Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA 2.8%
4/20 Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma 2.8%
8/15 What Has Led Bristol-Myers Squibb's Stock To Fall More Than 35% Over The Last 3 Years? [Forbes] 2.7%
TOP News Decliners
6/24
Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
-7.8%
3/11 Nationwide class actions are safe, thanks to the D.C. and 7th Circuits [Reuters] -7.1%
10/22 Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise [Yahoo! Finance News] -4.9%
3/6 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 04 Filed by: Elicker John E -4.4%
3/20 Bristol-Myers Squibb, Sanofi strike out in bid to stop Plavix litigation [Seeking Alpha] -4.3%
3/18 Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development -4.3%
2/26 Form 4 BRISTOL MYERS SQUIBB CO For: Feb 03 Filed by: Metcalfe Kathryn -4.0%
3/16 BMY Stock Dives As Investors Worry Coronavirus Could Delay A Key Drug [Investor's Business Daily] -3.6%
4/7 Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S. -3.6%
4/20 Bristol Myers Squibb's Cancer Drug Opdivo Successful in 2 Clinical Trials [The Motley Fool] -3.5%
3/11 Nationwide class actions are safe, thanks to the D.C. and 7th Circuits [Reuters] -7.1%
10/22 Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise [Yahoo! Finance News] -4.9%
3/6 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 04 Filed by: Elicker John E -4.4%
3/20 Bristol-Myers Squibb, Sanofi strike out in bid to stop Plavix litigation [Seeking Alpha] -4.3%
3/18 Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development -4.3%
2/26 Form 4 BRISTOL MYERS SQUIBB CO For: Feb 03 Filed by: Metcalfe Kathryn -4.0%
3/16 BMY Stock Dives As Investors Worry Coronavirus Could Delay A Key Drug [Investor's Business Daily] -3.6%
4/7 Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S. -3.6%
4/20 Bristol Myers Squibb's Cancer Drug Opdivo Successful in 2 Clinical Trials [The Motley Fool] -3.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: